2061 - Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders.
Saved in:
| Title: | 2061 - Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders. |
|---|---|
| Authors: | Gadgeel, S.M., Soria, J.C., Felip, E., Cobo, M., Lu, S., Syrigos, K., Lee, K.H., Göker, E., Georgoulias, V., Li, W., Guclu, S., Isla, D., Ardizzoni, A., Dupuis, N., Gibson, N., Krämer, N., Bühnemann, C., Solca, F., Ehrnrooth, E., Goss, G. |
| Source: | European Journal of Cancer. Feb2017 Supplement 1, Vol. 72, pS185-S185. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
